lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
254 rows where filing_period = "second_quarter", filing_year = 2013 and issue_code = "PHA" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, income_amount, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1401274 | PARRY, ROMANI, DECONCINI & SYMMS 22cf9f9b-6729-4ca8-8839-7b4d2c58d19f | 2T | PARRY, ROMANI, DECONCINI & SYMMS | 30792 | BRAIDWOOD MANAGEMENT, INC. | 2013 | second_quarter | PHA | Issues related to the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 1 | 2013-05-20T16:11:08.293000-04:00 | ||
| 1401282 | PARRY, ROMANI, DECONCINI & SYMMS 62a95ebf-7a7c-45a2-83b0-2db37e871756 | 2T | PARRY, ROMANI, DECONCINI & SYMMS | 30792 | DIAMONDBACK DRUGS | 2013 | second_quarter | PHA | Issues related to the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 1 | 2013-05-20T16:20:10.977000-04:00 | ||
| 1401286 | PARRY, ROMANI, DECONCINI & SYMMS 997802ff-308f-43af-8df5-bbef2d10ffc3 | 2T | PARRY, ROMANI, DECONCINI & SYMMS | 30792 | VETERINARY PHARMACIES OF AMERICA, INC. | 2013 | second_quarter | PHA | Issues related to the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 1 | 2013-05-20T16:34:13.347000-04:00 | ||
| 1401291 | PARRY, ROMANI, DECONCINI & SYMMS 784014c6-1a40-482c-9cc6-cc890ab5188b | 2T | PARRY, ROMANI, DECONCINI & SYMMS | 30792 | WEDGEWOOD VILLAGE PHARMACY, INC. | 2013 | second_quarter | PHA | Issues related to the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 1 | 2013-05-20T16:45:15.340000-04:00 | ||
| 1401307 | PARRY, ROMANI, DECONCINI & SYMMS 97180f1b-de8b-4e10-9e7c-456baf7320eb | 2T | PARRY, ROMANI, DECONCINI & SYMMS | 30792 | WOMEN'S INTERNATIONAL PHARMACY, INC. | 2013 | second_quarter | PHA | Issues related to the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 1 | 2013-05-20T17:05:18.880000-04:00 | ||
| 1401590 | LONG TERM CARE PHARMACY ALLIANCE c0ca3a18-96b9-41df-87a8-1f5a68db2e01 | 2T | LONG TERM CARE PHARMACY ALLIANCE | 400309443 | LONG TERM CARE PHARMACY ALLIANCE | 2013 | second_quarter | PHA | Medicare Part D | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 160000 | 0 | 1 | 2013-06-04T12:05:12.027000-04:00 | |
| 1402249 | CYBER SECURITY RESEARCH CONSULTANTS, LLC 3b3a1ce0-1ebe-490c-881f-90a20e9cd1b1 | Q2 | CYBER SECURITY RESEARCH CONSULTANTS, LLC | 91694 | PDFRAZER CONSULTING INC CANADIAN INTERNATIONAL PHARMACY ASSOCIATION | 2013 | second_quarter | PHA | Monitoring drug importation legislation | SENATE | 20000 | 0 | 0 | 2013-07-02T12:35:13.480000-04:00 | |
| 1402282 | INJURED WORKERS PHARMACY 1f021ac8-3c52-4bcd-b7d3-2ea08d27983b | Q2 | INJURED WORKERS PHARMACY | 400765309 | INJURED WORKERS PHARMACY | 2013 | second_quarter | PHA | Transparency of Pharmacy Benefits Managers (bill sponsored by Rep. McMorris-Rodgers and Senator Mark Pryor); Longshoreman and Harbor Workers Amendement Act of 2011sponsored by Senator Isakson. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2013-07-02T12:46:24.800000-04:00 | ||
| 1402453 | AMERICAN COLLEGE OF CLINICAL PHARMACY 4670cda4-d6af-4311-b1bd-61e74dbf7a6a | Q2 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2013 | second_quarter | PHA | Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 111725 | 0 | 0 | 2013-07-02T16:07:53.320000-04:00 | |
| 1402742 | VENABLE LLP 944879b8-a84e-4566-8432-c76beec8a774 | Q2 | VENABLE LLP | 39941 | ENDO PHARMACEUTICALS INC | 2013 | second_quarter | PHA | Issues related to tamper resistant formulation of pharmaceuticals drugs. The Life Sciences Jobs and Investment Act. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2013-07-03T16:55:17.880000-04:00 | |
| 1403233 | UNIVERSITY OF IOWA 8bb0490d-8531-450f-8557-c87606ae1355 | Q2 | UNIVERSITY OF IOWA | 49191 | UNIVERSITY OF IOWA | 2013 | second_quarter | PHA | Increased appropriations for systems to shorten the time between development of a drug and its release to the public FDA reform as it relates to drug development and research Collaborative research on drug development Human factors research related to neuropharmaceuticals | Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT) | 29312 | 0 | 0 | 2013-07-08T12:52:43.863000-04:00 | |
| 1403320 | THORSEN FRENCH ADVOCACY LLC a2fc354e-f093-4917-b6f3-3bad5a39cbf6 | Q2 | THORSEN FRENCH ADVOCACY LLC | 400599826 | ASTRAZENECA PHARMACEUTICALS LP | 2013 | second_quarter | PHA | Issues realted to access to pharmaceuticals. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2013-07-08T16:11:38.377000-04:00 | |
| 1404120 | CAPITOL HILL CONSULTING GROUP fe9e11d5-6549-45ac-bebc-d004274e068a | Q2 | CAPITOL HILL CONSULTING GROUP | 72053 | PURDUE PHARMA LLP | 2013 | second_quarter | PHA | Controlled Drug Substances Act (21 USC 13) Stop Tampering of Prescription Pills Act of 2013 (H.R. 486) | HOUSE OF REPRESENTATIVES,SENATE | 31500 | 0 | 0 | 2013-07-10T12:15:13.623000-04:00 | |
| 1404137 | CAPITOL HILL CONSULTING GROUP 63c4d585-7e15-427a-b065-aac04e8bd6f8 | Q2 | CAPITOL HILL CONSULTING GROUP | 72053 | PROFESSIONAL COMPOUNDING CENTERS OF AMERICA | 2013 | second_quarter | PHA | Compounding pharmacy and FDA issues Pharmaceutical Compounding Quality and Accounting Act (S. 959) | HOUSE OF REPRESENTATIVES,SENATE | 45000 | 0 | 0 | 2013-07-10T12:26:24.663000-04:00 | |
| 1404491 | DUTKO WORLDWIDE, LLC 0a96bb96-18c9-449b-af1d-3cdd8169e685 | Q2 | DUTKO WORLDWIDE, LLC | 12868 | NEWAYS INTERNATIONAL | 2013 | second_quarter | PHA | Monitor legislation pertaining to dietary supplements and pharmaceuticals, particularly the Food Safety Modernization Act (PL 111-353) and Patient Protection and Affordable Care Act (PL 111-148). | Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2013-07-10T20:01:28.467000-04:00 | |
| 1404612 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 370fe154-e056-4be4-9250-2d704f564021 | Q2 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 29403 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2013 | second_quarter | PHA | Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; mandatory recall authority of the FDA; Rx-to-OTC SwitchSupporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE | 290000 | 0 | 0 | 2013-07-11T09:56:40.260000-04:00 | |
| 1404807 | LNE GROUP 1a4919b1-8c69-4be0-b3f4-28eea72499a7 | Q2 | LNE GROUP | 308811 | OHIOGUIDESTONE (FORMALLY KNOWN AS GUIDESTONE) | 2013 | second_quarter | PHA | Lobbied on pharmacy issues | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2013-07-11T12:00:13.973000-04:00 | |
| 1404866 | UPS (UNITED PARCEL SERVICE) 78e0dd0c-419b-43de-a972-e0046438ed34 | Q2 | UPS (UNITED PARCEL SERVICE) | 39223 | UPS (UNITED PARCEL SERVICE) | 2013 | second_quarter | PHA | HR 1919 / S.959 Healthcare Supply Chain Safety related to Track & Trace legislation | Air Force, Dept of,Army, Dept of (Other),Commerce, Dept of (DOC),Executive Office of the President (EOP),Federal Aviation Administration (FAA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Navy, Dept of,SENATE,State, Dept of (DOS),Transportation, Dept of (DOT),Treasury, Dept of,U.S. Trade Representative (USTR),White House Office | 1201541 | 0 | 0 | 2013-07-11T12:28:30.807000-04:00 | |
| 1404907 | LNE GROUP 4b7bafcc-e48a-4c33-81dc-14a23b2acfe7 | Q2 | LNE GROUP | 308811 | INTRINSIQ MATERIALS | 2013 | second_quarter | PHA | Lobbied on pharmacy issues | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2013-07-11T12:48:43.403000-04:00 | |
| 1405105 | MCDERMOTT WILL & SCHULTE LLP 225dfbdc-0848-4400-b531-d1854ce61718 | Q2 | MCDERMOTT WILL & SCHULTE LLP | 24338 | ALLERGAN, INC. | 2013 | second_quarter | PHA | Issues related to Section 340B of the Public Health Service Act; FDA issues; health reform implementation | Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2013-07-11T14:55:05.490000-04:00 | |
| 1405111 | MASSACHUSETTS MEDICAL SOCIETY 0b38c9dc-2823-4137-9aa0-2e81237feec1 | Q2 | MASSACHUSETTS MEDICAL SOCIETY | 23975 | MASSACHUSETTS MEDICAL SOCIETY | 2013 | second_quarter | PHA | HR 1285, S 621 - Safe Prescribing Act of 2013, to amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug Drug Diversion issues including, reauthorization of the NASPER, appropriations for the Substance Abuse & Mental health | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE | 60000 | 0 | 0 | 2013-07-11T14:58:10-04:00 | |
| 1405295 | STANTON PARK GROUP f9cb26bf-85a7-426a-8b5c-e9a8f659a7f4 | Q2 | STANTON PARK GROUP | 83717 | ALKERMES, INC. | 2013 | second_quarter | PHA | increasing acceptance of medication assisted therapy in treating abuse of alcohol and opioid dependence | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2013-07-11T16:36:35.893000-04:00 | |
| 1405542 | RED+BLUE STRATEGIES 12163170-b240-4e77-8268-348df7ad91c3 | Q2 | RED+BLUE STRATEGIES | 400693064 | EXPRESS SCRIPTS INC. | 2013 | second_quarter | PHA | H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negatively impact access to mail order pharmacy Rules, regulations and guidance specific to prescription drug pricing, generic utilization and specialty pharmacy.Issues impacting PBMs in up coming health related legislation. Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. Changes in International Naming policies for generic medications. ACA-related regulations impacting new rules for Exchanges specific to the promulgation of the prescription drug benefits. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2013-07-12T11:34:52.797000-04:00 | |
| 1405560 | PARRY, ROMANI, DECONCINI & SYMMS c159a860-411e-43d2-8e55-733eda0bcf96 | Q2 | PARRY, ROMANI, DECONCINI & SYMMS | 30792 | POZEN, INC. | 2013 | second_quarter | PHA | Support legislation to provide incentives for new drug development. No specific bills pending. | HOUSE OF REPRESENTATIVES,SENATE | 36000 | 0 | 0 | 2013-07-12T11:55:03.530000-04:00 | |
| 1406459 | CARDINAL HEALTH, INC. e15f3100-ff77-4f4e-8c67-5935208baf2e | Q2 | CARDINAL HEALTH, INC. | 58055 | CARDINAL HEALTH INC | 2013 | second_quarter | PHA | S. 621/HR 1285; "Safe Prescribing Act of 2013" (All provisions, including but not limited to Section 2, related to the Physical Security Requirements for storing hydrocodone products.) | HOUSE OF REPRESENTATIVES,SENATE | 360000 | 0 | 0 | 2013-07-15T10:05:03.967000-04:00 | |
| 1406473 | APOTEX CORP. fc313776-8f9a-496a-86b4-82e5734be4c9 | Q2 | APOTEX CORP. | 310973 | APOTEX CORP. | 2013 | second_quarter | PHA | S. 504, The Fair and Immediate Release of Generics Act, provisions relating to market blockages caused by parked 180 day exclusivity periods S. 214, The Preserve Access to Affordable Pharmaceuticals Act, provisions relating to the legality of "reverse payment" patent settlementsFederal Trade Commission v. Actavis Supreme Court Case No. 12-416 as this case pertains to S. 504, S. 214, and to federal policy on "reverse payment" settlements Potential legislation relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing H.R. 1919, the Safeguarding America's Pharmaceutical Act of 2013, S. 959, the Pharmaceutical Compounding Quality and Accountability Act, Title II, Drug Supply Chain Security, provisions relating to the establishment of a federal track and trace system for pharmaceuticals Federal policy relating to the adoption of an electronic labeling system for pharmaceuticals, inlcuding as proposed in HR 1919 S. 1244, Fiscal Year 2014 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations bill, Title VI, Related Agency and Food and Drug Administration, provisions relating to the sequester's impact on the generic drug user fee program | Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE | 140000 | 0 | 0 | 2013-07-15T10:22:09.377000-04:00 | |
| 1406527 | PD FRAZER CONSULTING, INC. 2ae53d7f-26c4-4896-902b-57932ac22536 | Q2 | PD FRAZER CONSULTING, INC. | 65998 | CANADA INTERNATIONAL PHARMACY ASSOCIATION | 2013 | second_quarter | PHA | Monitor the development of proposed bills about the importation of prescription drugs. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2013-07-15T10:58:38.067000-04:00 | |
| 1406570 | WEXFORD STRATEGIC ADVISORS, INC. 8ec1a8ea-e272-4f17-838e-f73943450a26 | Q2 | WEXFORD STRATEGIC ADVISORS, INC. | 401047947 | P.D. FRAZER CONSULTING, INC., CANADIAN INTERNATIONAL PHARMACY ASSOCIATION | 2013 | second_quarter | PHA | Monitor the development of proposed bills about the importation of prescription drugs. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2013-07-15T11:18:01.893000-04:00 | |
| 1406606 | ANIMAL HEALTH INSTITUTE 5c3d2983-d63b-4c99-8d7e-6862d0fb80a0 | Q2 | ANIMAL HEALTH INSTITUTE | 4037 | ANIMAL HEALTH INSTITUTE | 2013 | second_quarter | PHA | Issues related to illegal drug compounding, including S959, Pharmaceutical Compounding Quality and Accountability Act.; Veterinary Drug Enforcement Administration issues - Veterinary Medicine Mobility Act of 2013. | HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR) | 50000 | 0 | 0 | 2013-07-15T11:29:16.807000-04:00 | |
| 1406792 | KATE MOSS e1d40fa9-de72-4280-bb4b-2bc8c78ce8e7 | Q2 | KATE MOSS | 25988 | CVS HEALTH | 2013 | second_quarter | PHA | Issues related to prescription drug abuseand drug supply chain safety | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2013-07-15T13:27:40.970000-04:00 | |
| 1407051 | BLUECROSS BLUESHIELD OF TENNESSEE fcf58b17-39ac-4eb4-864d-aafa2c30a273 | Q2 | BLUECROSS BLUESHIELD OF TENNESSEE | 6440 | BLUECROSS BLUESHIELD OF TENNESSEE | 2013 | second_quarter | PHA | General Pharmacy Issues | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2013-07-15T14:40:37.833000-04:00 | |
| 1407070 | PHILIP W. JOHNSTON ASSOCIATES 088f1f11-3a05-424e-a07f-0086be958115 | Q2 | PHILIP W. JOHNSTON ASSOCIATES | 400278335 | LUMARA HEALTH (FKA KV PHARMACEUTICAL COMPANY) | 2013 | second_quarter | PHA | Legislation regulating compounding pharmacies to improve patient safety. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2013-07-15T14:46:46.017000-04:00 | |
| 1407327 | ROCK & ASSOCIATES ab512380-0599-4611-bb04-5888bafbbf95 | Q2 | ROCK & ASSOCIATES | 33545 | WOMEN'S INTERNATIONAL PHARMACY | 2013 | second_quarter | PHA | S.959, legislation affecting the operation of compounding pharmacies and the availability of compounded medications. | HOUSE OF REPRESENTATIVES,SENATE | 9375 | 0 | 0 | 2013-07-15T16:04:39.283000-04:00 | |
| 1407332 | HEARTLAND SOLUTIONS GROUP, INC. 9e742772-54b7-457a-a477-ee2e85955dc9 | Q2 | HEARTLAND SOLUTIONS GROUP, INC. | 312133 | ZEBRA TECHNOLOGIES CORPORATION | 2013 | second_quarter | PHA | Any and all issues related to barcode, secure identification and real-time location systems. | HOUSE OF REPRESENTATIVES,SENATE | 48000 | 0 | 0 | 2013-07-15T16:04:41.080000-04:00 | |
| 1407402 | ROCK & ASSOCIATES eb9acebc-db43-492f-be6e-cbb9d4930a4a | Q2 | ROCK & ASSOCIATES | 33545 | BRAIDWOOD MANAGEMENT, INC. | 2013 | second_quarter | PHA | S.959, legislation affecting the operation of compounding pharmacies and the availability of compounded medications. | HOUSE OF REPRESENTATIVES,SENATE | 9375 | 0 | 0 | 2013-07-15T16:35:09.837000-04:00 | |
| 1407421 | ROCK & ASSOCIATES 7094df03-d02a-4234-962a-3ea487490c0f | Q2 | ROCK & ASSOCIATES | 33545 | CAPITOL HILL CONSULTING GROUP (ON BEHALF OF WELLNESS PHARMACY) | 2013 | second_quarter | PHA | S.959, legislation affecting the operation of compounding pharmacies and the availability of compounded medications. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2013-07-15T16:48:23.153000-04:00 | ||
| 1407460 | ROCK & ASSOCIATES 498fa068-3053-4d32-ac5b-da816d24776b | Q2 | ROCK & ASSOCIATES | 33545 | DIAMONDBACK DRUGS | 2013 | second_quarter | PHA | S.959, legislation affecting the operation of compounding pharmacies and the availability of compounded medications. | HOUSE OF REPRESENTATIVES,SENATE | 6750 | 0 | 0 | 2013-07-15T16:57:42.273000-04:00 | |
| 1407502 | ROCK & ASSOCIATES 1d8d2c2f-fa5e-420d-a3b4-822ebda287c5 | Q2 | ROCK & ASSOCIATES | 33545 | VETERINARY PHARMACIES OF AMERICA, INC. | 2013 | second_quarter | PHA | S.959, legislation affecting the operation of compounding pharmacies and the availability of compounded medications. | HOUSE OF REPRESENTATIVES,SENATE | 9375 | 0 | 0 | 2013-07-15T17:12:02.090000-04:00 | |
| 1407531 | ALZHEIMER'S FOUNDATION OF AMERICA ddca328a-ddb0-4476-8a43-ba64558dced6 | Q2 | ALZHEIMER'S FOUNDATION OF AMERICA | 323158 | ALZHEIMER'S FOUNDATION OF AMERICA | 2013 | second_quarter | PHA | CMS national coverage decision on PET imaging for AD diagnosis. | Administration on Aging,Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office | 26250 | 0 | 0 | 2013-07-15T17:21:14.817000-04:00 | |
| 1407540 | ROCK & ASSOCIATES b9b6673c-dc36-40e8-8941-fe4e67c331d7 | Q2 | ROCK & ASSOCIATES | 33545 | WEDGEWOOD VILLAGE PHARMACY, INC. | 2013 | second_quarter | PHA | S.959, legislation affecting the operation of compounding pharmacies and the availability of compounded medications. | HOUSE OF REPRESENTATIVES,SENATE | 9375 | 0 | 0 | 2013-07-15T17:26:18.517000-04:00 | |
| 1407548 | ALZHEIMER'S FOUNDATION OF AMERICA 85824621-1614-45ae-a2fb-8929456a67ec | Q2 | ALZHEIMER'S FOUNDATION OF AMERICA | 323158 | ALZHEIMER'S FOUNDATION OF AMERICA | 2013 | second_quarter | PHA | CMS national coverage decision on PET imaging for AD diagnosis. | Administration on Aging,Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office | 26250 | 0 | 0 | 2013-07-15T17:29:22.497000-04:00 | |
| 1407614 | THE OUTLAW GROUP 6768ad69-3655-4900-be24-afbaa80691bb | Q2 | THE OUTLAW GROUP | 46095 | SENTRY DATA SYSTEMS | 2013 | second_quarter | PHA | Congressional interest and efforts impacting the 340B prescription drug program. | HOUSE OF REPRESENTATIVES | 0 | 0 | 2013-07-15T19:27:01.607000-04:00 | ||
| 1407674 | GREATER NEW YORK HOSPITAL ASSOCIATION 013896f5-017b-43ef-ae2e-d8f020ec4e0b | Q2 | GREATER NEW YORK HOSPITAL ASSOCIATION | 16830 | GREATER NEW YORK HOSPITAL ASSOCIATION | 2013 | second_quarter | PHA | Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including drug shortage legislation, implementation of P.L. 112-144, medical device pricing and tax issues (including gag clauses), and preserving access to group purchasing organizations (GPOs); drug compounding bills (S.959 & H.R.2090); 340b HRSA guidance on the GPO exclusion (HRSA Release 2013-1); FDA mobile health guidance (FDA-2011-D-0530); track and trace bills (S.957 &H.R.1919). | Centers For Medicare and Medicaid Services (CMS),Federal Emergency Management Agency (FEMA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Internal Revenue Service (IRS),SENATE,White House Office | 290000 | 0 | 0 | 2013-07-16T09:30:27.253000-04:00 | |
| 1408022 | WHITMER & WORRALL, LLC 5c74551d-44d9-4b75-952e-e2ea52f736a0 | Q2 | WHITMER & WORRALL, LLC | 292892 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | 2013 | second_quarter | PHA | Issues related to monitoring healthcare reform. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,State, Dept of (DOS) | 30000 | 0 | 0 | 2013-07-16T12:07:18.650000-04:00 | |
| 1408081 | PRINTING INDUSTRIES OF AMERICA, INC. 18cfad10-03ee-4e18-a866-5391abf21314 | Q2 | PRINTING INDUSTRIES OF AMERICA, INC. | 32203 | PRINTING INDUSTRIES OF AMERICA INC | 2013 | second_quarter | PHA | Pharmaceutical labeling | Consumer Product Safety Commission (CPSC),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Government Printing Office (GPO),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Postal Rate Commission,Postal Regulatory Commission,SENATE,State, Dept of (DOS),Treasury, Dept of,U.S. Postal Service (USPS) | 128129 | 0 | 0 | 2013-07-16T12:31:44.067000-04:00 | |
| 1408390 | HAAKE & ASSOCIATES 43047ef2-9907-4fef-8ca2-7710a4c8abd7 | Q2 | HAAKE & ASSOCIATES | 17226 | JOHNSON & JOHNSON SERVICES INC. | 2013 | second_quarter | PHA | Policy and procurement matters related to vaccines | Air Force, Dept of,Army, Dept of (Other),Defense, Dept of (DOD),Navy, Dept of,U.S. Coast Guard (USCG),U.S. Marines | 30000 | 0 | 0 | 2013-07-16T14:42:51.667000-04:00 | |
| 1408458 | AMERICAN VETERINARY MEDICAL ASSOCIATION d82a496e-6d8f-44a4-bfd6-121a07bd16dc | Q2 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 3630 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 2013 | second_quarter | PHA | H.R. 1150 Preservation of Antibiotics for Medical Treatment Act; S. 959, Pharmaceutical Quality, Security, and Accountability Act; S. 622, Animal Drug and Animal Generic Drug User Fee Act; H.R.1407, Animal Drug User Fee Act; H.R. 1408 Animal Generic Drug User Fee Act; H.R. 1528/S. 1171 Veterinary Medicine Mobility Act; Fairness to Pet Owners Act/Veterinary Prescription writing. Inquiries to and discussions with Federal Trade Commission on veterinary pet prescriptions.Discussions with DEA regarding regulations impending practice of veterinary medicine; seeking clarification of interpretation of existing statute. Discussions with Congressional staff and FDA expressing the need for compounding of medications for use in animals. Discussions with Congressional staff in opposition to language regarding data collection being attached to the Animal Drug User Fee reauthorization language. S. 950/H.R. 1528, Veterinary Medicine Mobility Act of 2013 | Agriculture, Dept of (USDA),Defense, Dept of (DOD),Executive Office of the President (EOP),Federal Trade Commission (FTC),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Office of Management & Budget (OMB),SENATE | 190000 | 0 | 0 | 2013-07-16T14:56:22.517000-04:00 | |
| 1408559 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. ba75dbde-082c-449b-86fb-13f5fec29400 | Q2 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | AMERICAN SOCIETY OF HEMATOLOGY | 2013 | second_quarter | PHA | Issues related to drug shortages. | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 30000 | 0 | 0 | 2013-07-16T15:10:14.347000-04:00 | |
| 1408679 | WINSTON & STRAWN LLP d4c550b7-a054-479d-bb68-eb9362e30e0e | Q2 | WINSTON & STRAWN LLP | 41682 | FRESENIUS KABI USA (FORMERLY KNOWN AS APP PHARMACEUTICALS INC ) | 2013 | second_quarter | PHA | Represent the client on issues related to assuring a safe, reliable supply of heparin and also on patent matters, including settlements and extensions. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2013-07-16T15:25:00.310000-04:00 | ||
| 1408823 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 2b2fa3e8-86ab-4923-ad0f-75b776da0284 | Q2 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | THE HEMOPHILIA ALLIANCE | 2013 | second_quarter | PHA | issues related to the 340B drug discount program. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2013-07-16T16:01:04.417000-04:00 | |
| 1408861 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 847d1c4c-00e3-4677-89aa-e1bbf91400bd | Q2 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL HEMOPHILIA FOUNDATION | 2013 | second_quarter | PHA | Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program. HR 460 - Patients Access to Treatment Act | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 50000 | 0 | 0 | 2013-07-16T16:11:21.973000-04:00 | |
| 1408901 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 0707585d-0848-482f-9e83-ad0fc4286b99 | Q2 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL ASSOCIATION OF EPILEPSY CENTERS | 2013 | second_quarter | PHA | Issues related to anti-epileptic drugs. | Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 10000 | 0 | 0 | 2013-07-16T16:13:30.910000-04:00 | |
| 1409467 | NAHIGIAN STRATEGIES, LLC c14d4a26-1e37-40c3-9edc-dd4883f58e2b | Q2 | NAHIGIAN STRATEGIES, LLC | 322897 | TEVA PHARMACEUTICALS USA INC | 2013 | second_quarter | PHA | Generic and brand drug patent and antitrust issues. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2013-07-17T10:26:29.850000-04:00 | |
| 1409887 | CAPITOLOGIC LLC afb6d9a3-f543-4259-9a09-dca3fc5508b9 | Q2 | CAPITOLOGIC LLC | 400426045 | BULALAW, LLC | 2013 | second_quarter | PHA | Federal funding of illegal prescription drug market interventions | Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institute of Justice,Office of Justice Program,SENATE | 0 | 0 | 2013-07-17T12:38:23.950000-04:00 | ||
| 1409951 | MR. VINCENT A. PANVINI 1aea7349-08d9-4793-9804-3edd03c46919 | Q2 | MR. VINCENT A. PANVINI | 401008845 | ELI LILLY AND COMPANY | 2013 | second_quarter | PHA | Medicare Pt D, Transpacific Partnership | HOUSE OF REPRESENTATIVES | 0 | 0 | 2013-07-17T13:15:47.153000-04:00 | ||
| 1409961 | INDEPENDENT PHARMACY COOPERATIVE a1c7683f-e8c6-4eb8-8427-45c907ca5b6f | Q2 | INDEPENDENT PHARMACY COOPERATIVE | 313098 | INDEPENDENT PHARMACY COOPERATIVE | 2013 | second_quarter | PHA | Tax Payer Relief Act 2013 Implementation of Diabetic Supply Reimbursement Changes SB 959 Pharmaceutical Compounding Quality and Accountability Act | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2013-07-17T13:22:49.443000-04:00 | ||
| 1409977 | MR. VINCENT A. PANVINI 08bdf48d-a9b3-44eb-a78d-0e7666338cb2 | Q2 | MR. VINCENT A. PANVINI | 401008845 | PHRMA | 2013 | second_quarter | PHA | Medicare Part D, Transpacific Partnership | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2013-07-17T13:30:56.610000-04:00 | |
| 1410195 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 797f28a0-1deb-487e-b89c-5e37c54ec472 | Q2 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) | 24486 | ALLIED MEDICAL SUPPLY, INC. | 2013 | second_quarter | PHA | Issues affecting resellers of pharmaceutical products in HR 1919 and S. 957 | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2013-07-17T14:36:25.090000-04:00 | |
| 1410345 | MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY 260cf8b5-ca6e-4fc9-8a03-5c0ba863ea89 | Q2 | MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY | 62277 | MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY | 2013 | second_quarter | PHA | HR 1919 Safeguarding America's Pharmaceutical Act of 2013 and the Senate "track and trace" legislation | HOUSE OF REPRESENTATIVES,SENATE | 290000 | 0 | 0 | 2013-07-17T15:02:29.897000-04:00 | |
| 1410380 | SMITH GARSON FKA SMITH DAWSON & ANDREWS 6ce47467-e72f-48f9-a21a-43a834c1cf4c | 2A | SMITH GARSON FKA SMITH DAWSON & ANDREWS | 35707 | CURE PHARMACEUTICALS | 2013 | second_quarter | PHA | Discussed federal government unpaid invoice from 2011 & 2012. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2013-07-17T15:06:42.787000-04:00 | ||
| 1410581 | RED+BLUE STRATEGIES 3ffc7bf1-2073-4cea-b058-ef1bba60d40c | Q2 | RED+BLUE STRATEGIES | 400693064 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2013 | second_quarter | PHA | H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negative impact peoples access to prescription medications through mail. Issues related to the practice of giving coupons for certain prescription medications.Ongoing discussions in the Congress regarding track and trace policies to increase safety in the nation's prescription drug supply chain. CMS call letter focused on changes in policies regarding mail order and pharmacy networks. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2013-07-17T15:39:10.087000-04:00 | |
| 1410612 | SOCIETY OF CHEMICAL MANUFACTURERS & AFFILIATES f013e909-4d8a-4996-8f5e-c681a4f55fcd | Q2 | SOCIETY OF CHEMICAL MANUFACTURERS & AFFILIATES | 37538 | SOCIETY OF CHEMICAL MANUFACTURERS & AFFILIATES | 2013 | second_quarter | PHA | Activities related to concerns that the federal sequestration will negatively impact the implementation of the Food and Drug Administration's Generic Drug User Fee Act. | Environmental Protection Agency (EPA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,SENATE | 41000 | 0 | 0 | 2013-07-17T15:45:24.757000-04:00 | |
| 1410677 | ACADEMY OF MANAGED CARE PHARMACY ac1134f1-abf1-4629-a5dc-f4aac471fe52 | Q2 | ACADEMY OF MANAGED CARE PHARMACY | 48793 | ACADEMY OF MANAGED CARE PHARMACY | 2013 | second_quarter | PHA | S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs HR 2186 - requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy. S 957 legislation establishes a uniform national policy for the drug supply chain HR 1919 legislation provides enhanced securityin the drug distribution chain | HOUSE OF REPRESENTATIVES,SENATE | 200000 | 0 | 0 | 2013-07-17T15:51:41.577000-04:00 | |
| 1410734 | KOUNTOUPES DENHAM CARR & REID, LLC 5447e2e0-edb3-4f85-bc3c-c513570c706f | Q2 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2013 | second_quarter | PHA | Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient common in popular cold and allergy medications, and opposition to prescription requirements. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2013-07-17T16:04:08.537000-04:00 | |
| 1411146 | KAISER FOUNDATION HEALTH PLAN INC. 199f75e4-49c2-4de9-89e8-6df2b486653b | Q2 | KAISER FOUNDATION HEALTH PLAN INC. | 21027 | KAISER FOUNDATION HEALTH PLAN INC | 2013 | second_quarter | PHA | S3187 - Food and Drug Administration Safety and Innovation Act: A bill to amend the Federal Food, Drug and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish user-fee programs for generic drugs and biosimilars, and for other purposes. Sponsor: Harkin (IA) | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 120000 | 0 | 0 | 2013-07-17T18:04:52.080000-04:00 | |
| 1411242 | UNIVERSITY OF CONNECTICUT edebe444-d005-482c-852b-99122f7656b1 | Q2 | UNIVERSITY OF CONNECTICUT | 39382 | UNIVERSITY OF CONNECTICUT | 2013 | second_quarter | PHA | S.1244/H.R.2410, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2014, Monitor FDA salaries and expense issues; and extramural research. | Education, Dept of,HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2013-07-17T18:58:16.773000-04:00 | |
| 1411787 | THE OB-C GROUP, LLC 0bec6cd1-b99c-499d-be71-289983ca9f8c | Q2 | THE OB-C GROUP, LLC | 29802 | ELI LILLY | 2013 | second_quarter | PHA | No specific bill number: matters relating to pharmaceutical manufacturers including Medicare Part D. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2013-07-18T09:59:12.700000-04:00 | |
| 1411872 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 499f0f3a-f2fd-4d25-99d4-6f7d12310e1a | Q2 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) | 28776 | HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) | 2013 | second_quarter | PHA | Rx Pedigree (S. 959, S. 957, H.R. 1919, H.R. 2186); Prescription Drug Monitoring Programs; Drug Abuse (S. 348); Hydrocodone Rescheduling (H.R. 1285, S. 621); Dextromethorphan (S. 644); Prescription Drug Abuse (S. 1277); Drug Shortages - Gray Market (H.R. 1958); Counterfeit Drugs; Importation of Prescription Drugs | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 358000 | 0 | 0 | 2013-07-18T10:12:38.330000-04:00 | |
| 1411909 | BROWN RUDNICK LLP 2aa864bb-302a-4846-bd93-e2d5412a68bb | Q2 | BROWN RUDNICK LLP | 287895 | HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC | 2013 | second_quarter | PHA | S. 621 & H.R. 1285 - Safe Prescribing Act of 2013; H.R. 1919 - Safeguarding America's Pharmaceuticals Act of 2013; S. 957 & S. 959 - The Drug Supply Chain Security Act; S. 1277- Combating Prescription Drug Abuse Act | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2013-07-18T10:24:51.007000-04:00 | |
| 1412016 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 6f5da635-888a-4966-80b9-238f5016ca56 | Q2 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 31348 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 2013 | second_quarter | PHA | Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio).Regulatory and proposed legislative changes to Medicare part D including pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Regulatory Implementation of the HITECH Act. FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs, 340B program. Issues related to the compounding of certain drugs. S. 77, Prescription Drug and Health Improvement Act S. 557, Medication Therapy Management Empowerment Act H.R. 460, Patients Access to Treatments Act H.R. 1188, Preserving Our Hometown Independent Pharmacies Act H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 1024, Medication Therapy Management Empowerment Act S.867, Medicare Prescription Drug Program Integrity and Transparency Act | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE | 559764 | 0 | 0 | 2013-07-18T10:46:31.207000-04:00 | |
| 1412354 | DELAHUNT GROUP, LLC 57b68015-51bb-4fcd-99f3-b96d27e05fd9 | Q2 | DELAHUNT GROUP, LLC | 401066001 | HEALIANCE PHARMACEUTICALS | 2013 | second_quarter | PHA | innovative diabetes treatment | HOUSE OF REPRESENTATIVES,Natl Security Agency (NSA),SENATE,State, Dept of (DOS),Treasury, Dept of | 45000 | 0 | 0 | 2013-07-18T11:47:03.033000-04:00 | |
| 1412557 | BROWN RUDNICK LLP 23dc5730-4ad0-4d9e-a20f-f4479501add5 | 2A | BROWN RUDNICK LLP | 287895 | HOSPIRA, INC. | 2013 | second_quarter | PHA | H.R. 486- relating to the compounding of drug products House Discussion Draft amending 503A of FFDCA with respect to pharmacy compounding | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2013-07-18T12:11:23.250000-04:00 | |
| 1412597 | ENDO INTERNATIONAL 9306a16e-7129-4809-9f90-f455b17bc76d | Q2 | ENDO INTERNATIONAL | 40011075 | ENDO INTERNATIONAL | 2013 | second_quarter | PHA | Issues related to tamper resistant formulation of pharmaceutical drugs Life Sciences Jobs and Investment Act | HOUSE OF REPRESENTATIVES,SENATE | 450000 | 0 | 0 | 2013-07-18T12:16:36.027000-04:00 | |
| 1412666 | RUBICON ADVISORS, LLC fa95d955-0e43-498b-96d1-ef3421ffa928 | Q2 | RUBICON ADVISORS, LLC | 315091 | TEVA PHARMACEUTICALS USA | 2013 | second_quarter | PHA | Patent Settlements H.R. 1432, Generic Biologies S H.R. 1695, H.R. 5629, Physican Payment Sunshine Act S 2029, Patent Reform H.R. 1908, Import Safety Act H.R. 3100 Affodable Health Choices Act | HOUSE OF REPRESENTATIVES,SENATE | 105000 | 0 | 0 | 2013-07-18T12:32:01.297000-04:00 | |
| 1412682 | RUBICON ADVISORS, LLC ec549a9b-be7c-487d-b53b-4102598da033 | Q2 | RUBICON ADVISORS, LLC | 315091 | WATSON PHARMACEUTICALS INC | 2013 | second_quarter | PHA | Patent Reform H.R. 1908, Import Safety Act H.R. 2100 Affordable Health Choices Act Patent Settlements H.R. 1432 S 316 Generic Biologics S 1685 H.R. 5629 Physician Payment Sunshine Act S 2029 | HOUSE OF REPRESENTATIVES,SENATE | 98000 | 0 | 0 | 2013-07-18T12:37:09.150000-04:00 | |
| 1412683 | RUBICON ADVISORS, LLC 38c3715b-7979-400f-8711-e2fa1570511a | Q2 | RUBICON ADVISORS, LLC | 315091 | STATE MUTUAL INSURANCE COMPANY | 2013 | second_quarter | PHA | Pharmacy - Compounding | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2013-07-18T12:38:09.777000-04:00 | |
| 1412711 | RUBICON ADVISORS, LLC 1af79f94-2749-4ea6-b514-fe2985284ec1 | Q2 | RUBICON ADVISORS, LLC | 315091 | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2013 | second_quarter | PHA | Physician Payment Sunshine Act S 2029 Patent Settlements H.R. 14328 .316 Affordable Healthcare Choices Act | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2013-07-18T12:45:19.567000-04:00 | |
| 1412787 | ALCALDE & FAY a9c1b9eb-db41-47e9-b5af-c9213244b693 | Q2 | ALCALDE & FAY | 818 | CITY OF KENMORE, WASHINGTON | 2013 | second_quarter | PHA | DEA regulations on disposal of controlled substances; Marijuana Legalization issues; White House Office of National Drug Control Policy | Army, Dept of (Corps of Engineers),Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE,Transportation, Dept of (DOT),White House Office | 20000 | 0 | 0 | 2013-07-18T13:01:50.810000-04:00 | |
| 1412847 | THORN RUN PARTNERS 966b026b-8c1b-4871-ab57-2ba23df964e5 | 2T | THORN RUN PARTNERS | 400534596 | LONG TERM CARE PHARMACY ALLIANCE | 2013 | second_quarter | PHA | Issues related to short-cycle dispensing. Issues related to PBM audit legislation. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 1 | 2013-07-18T13:15:13.250000-04:00 | |
| 1412855 | MEHLMAN CONSULTING, INC. 43410dbe-140b-46f4-bbe5-51fd2b2e1381 | Q2 | MEHLMAN CONSULTING, INC. | 284950 | PROCTER & GAMBLE | 2013 | second_quarter | PHA | Preventing Abuse of Cough Treatments Act of 2013 (S. 644) | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2013-07-18T13:16:16.563000-04:00 | |
| 1412866 | KNIGHT CAPITOL CONSULTANTS b5afc4e5-1fab-4fe9-9733-9f258baa528f | Q2 | KNIGHT CAPITOL CONSULTANTS | 40036301 | GENZYME CORPORATION | 2013 | second_quarter | PHA | Adequate funding for programs of the Food and Drug Administration, including implementation of the Prescription Drug User Fee Act (FY 2014 appropriations for the FDA, H.R. 2410/S. 1244). Assess potential impact of sequestration on public health/food and drug programs (FY 2014 appropriations for HHS, S. 1284). | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2013-07-18T13:19:22.280000-04:00 | |
| 1412870 | HOSPIRA, INC. 4de1cb7a-248f-467a-8144-20469bf77001 | Q2 | HOSPIRA, INC. | 318711 | HOSPIRA INC | 2013 | second_quarter | PHA | H.R. 486 - relating to the compounding of drug products House Discussion Draft amending 503A of FFDCA with respect to pharmacy compounding S. 959 Compounding and Pedigree bill | HOUSE OF REPRESENTATIVES,SENATE | 240000 | 0 | 0 | 2013-07-18T13:19:23.217000-04:00 | |
| 1412914 | ELI LILLY AND COMPANY b9e02363-d45d-489a-824c-41f27c0ac84f | Q2 | ELI LILLY AND COMPANY | 13392 | ELI LILLY AND COMPANY | 2013 | second_quarter | PHA | Hospital discounts (HR 3590) | Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR) | 1965000 | 0 | 0 | 2013-07-18T13:24:37.947000-04:00 | |
| 1413039 | RED+BLUE STRATEGIES d17ef4c1-f56f-4466-a326-779369b71083 | Q2 | RED+BLUE STRATEGIES | 400693064 | PEW CHARITABLE TRUSTS | 2013 | second_quarter | PHA | Issues related to continuing to increase the supply of new and innovative antibiotics that will help to treat the myriad antibiotic resistant strains of bugs like MRSA.H.R. 933 - Consolidation and Further Continuing Appropriations Act of 2013 - Focused on funding for the FDA, CDC and other public health related industries. H.R. 2186 - VALID Compounding Act - Focused on increasing safety for compounded drugs S. 959 - Pharmaceutical Compounding Quality and Accountability Act - Focused on compounding and continued work on issues related to downstream supply chain safety of prescription medications Continued work on issues related to downstream supply chain safety of prescription medications | Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2013-07-18T14:02:41.137000-04:00 | |
| 1413307 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION f306b6d0-e7e2-493a-9ebd-276ade892b37 | Q2 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 27478 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 2013 | second_quarter | PHA | H.R. 2375- Transparency and Accountability in Medicare Bidding Act of 2013; Fairness for Small Pharmacies in Preferred Networks; Repeal of National Mail Order Program for Diabetes Testing Supplies Home Delivery; S.644- The Preventing Abuse of Cough Treatments Act of 2013; H.R. 1285- To Amend the Controlled Substance Act to Make Any Substance Containing Hydrocodone a Schedule II Drug; S.867- The Medicare Prescription Drug Program Integrity and Transparency Act of 2013;S.621- The Safe Prescribing Act of 2013; H.R. 1024- The Medication Therapy Management Empowerment Act of 2013; H.R. 1188- The Preserving Our Hometown Independent Pharmacies Act of 2013; S. 959, Pharmaceutical Compounding Quality and Accountability Act; S. 957- Drug Supply Chain Security Act; H.R.1919- Safeguarding America's Pharmaceuticals Act of 2013; Discussion House Draft Legislation on Compounded Drugs, Prescription Drug Diversion and Abuse; TRICARE Pharmacy Benefit/Provisions; Medicaid Reimbursment Cuts | Agency for Healthcare Research & Quality (AHRQ),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE | 210000 | 0 | 0 | 2013-07-18T14:42:26.353000-04:00 | |
| 1413374 | CAPITOL HILL CONSULTING GROUP 2b6f26d4-a467-4cce-b1ca-56fb49310645 | Q2 | CAPITOL HILL CONSULTING GROUP | 72053 | ROCK & ASSOCIATES | 2013 | second_quarter | PHA | Compounding pharmacy and FDA issues | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2013-07-18T14:50:55.707000-04:00 | ||
| 1413533 | CAPITOL HILL CONSULTING GROUP b0584572-9f43-4388-8cee-8abbad00fc41 | Q2 | CAPITOL HILL CONSULTING GROUP | 72053 | WELLNESS PHARMACY | 2013 | second_quarter | PHA | Compounding pharmacy and FDA issues; S959, Pharmaceutical Compounding Quality & Accountability Act | HOUSE OF REPRESENTATIVES,SENATE | 8000 | 0 | 0 | 2013-07-18T15:05:59.963000-04:00 | |
| 1413560 | PRIME POLICY GROUP c99e0cb8-633b-45c1-9e0d-3916973e4d59 | Q2 | PRIME POLICY GROUP | 400532589 | GLAXOSMITHKLINE | 2013 | second_quarter | PHA | Hearing in Energy and Commerce Committee. Drug supply chain. | HOUSE OF REPRESENTATIVES | 40000 | 0 | 0 | 2013-07-18T15:10:15.237000-04:00 | |
| 1413756 | HANCE SCARBOROUGH eec6e444-d4de-46fe-9e0e-e08f7ee9e276 | Q2 | HANCE SCARBOROUGH | 17443 | ALLIANCE OF INDEPENDENT PHARMACISTS - TEXAS | 2013 | second_quarter | PHA | Federal legislation affecting the practice of pharmacy and FDA regulation of compounded drugs. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2013-07-18T15:29:39.770000-04:00 | |
| 1414060 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING e7ef17e8-15fb-4ef7-85e0-a76036d3e115 | Q2 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 35968 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2013 | second_quarter | PHA | Pharmacy compounding of radiopharmaceuticals; S. 959, Pharmaceutical Quality, Security, and Accountability Act), nuclear medicine provisions. | Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Nuclear Regulatory Commission (NRC),SENATE | 110000 | 0 | 0 | 2013-07-18T16:06:01.447000-04:00 | |
| 1414155 | HANCE SCARBOROUGH c346d9d5-4dd7-49be-bb60-9cd0f3cd8af0 | Q2 | HANCE SCARBOROUGH | 17443 | INTRATHECAL CUSTODY ACCOUNT SUPPORTERS (INFORMAL COALITION) | 2013 | second_quarter | PHA | Monitored legislation related to physician control and patient access to intrathecal pump applications for patients with chronic pain. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2013-07-18T16:17:41.497000-04:00 | |
| 1414162 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. 5ec31bf3-96ac-4cc5-9e74-15e2569f14c9 | Q2 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. | 4653 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. | 2013 | second_quarter | PHA | Proposals relating to the regulation of direct to consumer prescription drug advertising | Commerce, Dept of (DOC),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,Natl Telecommunications & Information Administration (NTIA),SENATE | 470000 | 0 | 0 | 2013-07-18T16:18:44.357000-04:00 | |
| 1414893 | ARENTFOX SCHIFF LLP 5355ee21-2ad5-40e6-8146-50862a17b1b4 | Q2 | ARENTFOX SCHIFF LLP | 4208 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2013 | second_quarter | PHA | Pharmacy compounding of medications S. 959 (Pharmaceutical Quality, Security, and Accountability Act), entire bill | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2013-07-18T18:07:54.410000-04:00 | |
| 1415053 | EMPIRE CONSULTING GROUP 77ebc2d1-8547-48a6-a40b-8893694e722b | Q2 | EMPIRE CONSULTING GROUP | 400703105 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2013 | second_quarter | PHA | Issues relating to the Medicare Prescription Drug Act; issues relating to the Affordable Care Act; issues relating to the Independent Payment Advisory Board; H.R. 1588, "Medicare Drug Savings Act of 2013"; H.R. 1919, "Safeguarding America's Pharmaceutical Act of 2013"; and intellectual property issues. | HOUSE OF REPRESENTATIVES | 30000 | 0 | 0 | 2013-07-18T18:31:44.610000-04:00 | |
| 1415257 | THE INGRAM GROUP LLC 77839028-8363-432b-bac1-06afdb25e281 | Q2 | THE INGRAM GROUP LLC | 400577737 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | 2013 | second_quarter | PHA | Issues related to pharmaceutical importation, issues related to generic drugs, and S.CON.RES.8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2014, revising the appropriate budgetary levels for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023. Issues related to the Drug Supply Chain Security Act of 2013 S.957. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2013-07-18T22:17:58.340000-04:00 | |
| 1416109 | NOVO NORDISK INC. 6758fde1-a069-4a3e-b80b-81e329433ae6 | Q2 | NOVO NORDISK INC. | 284790 | NOVO NORDISK INC. | 2013 | second_quarter | PHA | H.R.1919 Safeguarding America's Pharmaceuticals Act of 2013 and S.959 Pharmaceutical Compounding Quality and Accountability Act (for track and trace supply chain provisions); issues regarding biosimilars; 340B | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Veterans Affairs, Dept of (VA) | 640000 | 0 | 0 | 2013-07-19T10:22:44.750000-04:00 | |
| 1416223 | COVIDIEN LP 2d45c420-5f89-4213-9818-f9d1a1eef06c | Q2 | COVIDIEN LP | 319778 | COVIDIEN LP | 2013 | second_quarter | PHA | Issues involving controlled substances and pain and addiction drugs generally. | Energy, Dept of,Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE,State, Dept of (DOS) | 760000 | 0 | 0 | 2013-07-19T10:38:34.847000-04:00 | |
| 1416612 | RASKY PARTNERS, INC. 84943093-4f61-46b4-b7de-1729a95b1fd7 | 2T | RASKY PARTNERS, INC. | 297410 | ELI LILLY AND CO | 2013 | second_quarter | PHA | Monitor biologics related issues, Medicare Part D | HOUSE OF REPRESENTATIVES,SENATE | 0 | 1 | 2013-07-19T11:19:05.893000-04:00 | ||
| 1416671 | ARKEMA INC. AND ITS AFFILIATES (FKA ARKEMA INC.) da7b14a8-2102-4a50-957d-887990555989 | Q2 | ARKEMA INC. AND ITS AFFILIATES (FKA ARKEMA INC.) | 13370 | ARKEMA INC. AND ITS AFFILIATES (FKA ARKEMA INC.) | 2013 | second_quarter | PHA | Food and Drug Administration pharmaceuticals issues | Agriculture, Dept of (USDA),Defense, Dept of (DOD),Energy, Dept of,Environmental Protection Agency (EPA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),Office of Science & Technology Policy (OSTP),SENATE,State, Dept of (DOS),Surface Transportation Board (STB),Transportation, Dept of (DOT),U.S. Trade Representative (USTR) | 140000 | 0 | 0 | 2013-07-19T11:26:33.933000-04:00 | |
| 1416952 | AMERICAN ASSOCIATION OF NURSE PRACTITIONERS 299bca32-25b2-4326-9f42-e9277ef126ed | Q2 | AMERICAN ASSOCIATION OF NURSE PRACTITIONERS | 401040928 | AMERICAN ASSOCIATION OF NURSE PRACTITIONERS | 2013 | second_quarter | PHA | Legislation and policies relating to: FDA Drug Safety and Risk Management Advisory Committee January 25 recommendation to reschedule hydrocodone as a Schedule II controlled substance H.R. 1285 - To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drugS. 621 Safe Prescribing Act H.R. 1919 - Safeguarding America's Pharmaceuticals Act H.R. 2186 VALID Compounding Act S. 959 Pharmaceutical Compounding Quality and Accountability Act | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE,White House Office | 84089 | 0 | 0 | 2013-07-19T11:44:20.793000-04:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);